Allogene Therapeutics Inc. (NASDAQ:ALLO) is one of the best growth stocks under $10 to invest in. On April 21, Allogene ...
The average one-year price target for Allogene Therapeutics (NasdaqGS:ALLO) has been revised to $8.83 / share. This is an increase of 16.66% from the prior estimate of $7.57 dated April 12, 2026. The ...
Therapy-related MDS/AML is an increasingly recognized, often fatal late complication after prolonged ...
Stocktwits on MSN
ALLO stock hits 2-year highs – analyst calls Allogene’s phase 2 trial data to treat lymphoma a ‘home run’
The interim data showed that cancer DNA levels dropped by 97.7% in the Cema-Cel group, while rising by 26.6% in the observation group. ・Allogene said the trial is ongoing across more than 60 sites and ...
Allogeneic stem cell transplant for multiple myeloma (MM) is one treatment associated with long-term disease-free survival. The high incidence of treatment-related mortality and relapses, however, are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results